![Hepatitis B Virus [HBV] Market - In-Depth Insights & Analysis](/site/templates/images/rd-default-image.png)
Global Hepatitis B Virus [HBV] Market Overview
Hepatitis B Virus [HBV] Market size is projected to reach USD XX Million by 2028 from an estimated USD XX Million in 2021, growing at a CAGR of xx% globally.Hepatitis B is a type of hepatitis virus that causes liver damage. It spreads through the body's fluids and blood. It is most usually transmitted through unprotected sex, from a mother to her child after birth, or by contaminated needles. It frequently causes no noticeable symptoms in adults and can disappear in a matter of months if left untreated. Children are more likely than adults to develop a long-term (chronic) infection. Children and adults with persistent infections might become extremely unwell and die if they do not receive proper treatment and care. Hepatitis B infection acquired in maturity causes chronic hepatitis in less than 5% of instances, but infection in infancy and early childhood causes chronic hepatitis in approximately 95% of cases. The hepatitis B virus has an incubation period of 30 to 180 days. The virus can be detected 30 to 60 days after infection and can persist and progress to chronic hepatitis B, particularly if it is transmitted during childhood or adolescence. There is a safe and effective vaccine available that provides 90% to 100% protection against hepatitis B. Preventing hepatitis B infection lowers the chance of complications like chronic illness and liver cancer. Because the COVID-19 pandemic caused people to ignore HBV testing, it is projected that the number of HBV cases will rise in the forecasted period, boosting the market's development.
Covid-19 Impact On Hepatitis B Virus [HBV] Market
The COVID-19 pandemic caused by the SARS-CoV-2 virus has resulted from a plethora of interventions aimed at reducing the public health impact of this virus. However, there is a growing body of evidence from both high-income and low-income nations on the broader effects of such interventions on economic and public health inequities, as well as on pre-existing programs targeting endemic infections. Even before COVID-19, only about 1% of viral hepatitis cases in Sub-Saharan Africa were diagnosed. As a result, while the pandemic may exacerbate difficulties in identifying infections, the impact of disrupted vaccination efforts, PMTCT programs, and antiviral treatment on the HBV epidemic will likely be higher in some regions of the world than reduced diagnostic capacity. The diversion of cash, human resources, and infrastructure to the COVID-19 response, as well as lower demand as a result of travel restrictions and fear of contracting COVID-19 in healthcare settings, has hampered access to healthcare, including testing and screening programs of HBV. Due to a lack of medical resources, the pandemic had a significant impact on HBV treatment methods. To summarize, with the growing vaccination rate, the demand for HBV treatment is expected to increase in the forecasted period thus, supporting the growth of the market.
Market Segmentation
Players Covered in Hepatitis B Virus [HBV] market are :
- F Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- Dicerna Pharmaceuticals
- Roche
- Arbutus Pharma
- Novartis AG
- AstraZeneca
- Bayer AG
- Others
Key Industry Developments of Hepatitis B Virus [HBV] Market
In December 2021, Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced the start of clinical trials for chronic hepatitis B virus (HBV) infection. This project has been undertaken to evaluate the efficacy of the triple combination doses of ATI-2173, AB-729, and Tenofovir Disoproxil Fumarate in patients.
In March 2021, Dicerna Pharmaceuticals and Roche have begun a Phase II combo trial of RG6346, an experimental GalXC RNAi candidate, for the treatment of chronic hepatitis B virus (HBV) infection.
| Hepatitis B Virus [HBV] Market - In-Depth Insights & Analysis | |||
|---|---|---|---|
| Segmentations | by Type |
| |
| by Type |
| ||
| by End Users |
| ||
| by Region |
| ||
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Drug Class
3.2 By Type
3.3 By End Users
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
3.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 4: Hepatitis B Virus [HBV] Market by Drug Class
4.1 Hepatitis B Virus [HBV] Market Overview Snapshot and Growth Engine
4.2 Hepatitis B Virus [HBV] Market Overview
4.3 Nucleotide Analog Reverse Transcriptase Inhibitors
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size (2016-2028F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Nucleotide Analog Reverse Transcriptase Inhibitors: Grographic Segmentation
4.4 Monoclonal Antibody
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size (2016-2028F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Monoclonal Antibody: Grographic Segmentation
4.5 Interferon
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size (2016-2028F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Interferon: Grographic Segmentation
4.6 Non-structural Protein 5A (NS5A) Inhibitors
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size (2016-2028F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Non-structural Protein 5A (NS5A) Inhibitors: Grographic Segmentation
4.7 Nucleotide Analog NS5B Polymerase Inhibitors
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size (2016-2028F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Nucleotide Analog NS5B Polymerase Inhibitors: Grographic Segmentation
4.8 Multi-Class Combination
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size (2016-2028F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Multi-Class Combination: Grographic Segmentation
4.9 Others
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size (2016-2028F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Others: Grographic Segmentation
Chapter 5: Hepatitis B Virus [HBV] Market by Type
5.1 Hepatitis B Virus [HBV] Market Overview Snapshot and Growth Engine
5.2 Hepatitis B Virus [HBV] Market Overview
5.3 Therapeutics
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Therapeutics: Grographic Segmentation
5.4 Vaccine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Vaccine: Grographic Segmentation
Chapter 6: Hepatitis B Virus [HBV] Market by End Users
6.1 Hepatitis B Virus [HBV] Market Overview Snapshot and Growth Engine
6.2 Hepatitis B Virus [HBV] Market Overview
6.3 Men
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Men: Grographic Segmentation
6.4 Women
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Women: Grographic Segmentation
6.5 Children
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Children: Grographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Hepatitis B Virus [HBV] Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Ansoff Matrix
7.1.5 Hepatitis B Virus [HBV] Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Hepatitis B Virus [HBV] Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 F HOFFMANN-LA ROCHE LTD
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 MERCK & CO. INC.
7.4 GILEAD SCIENCES INC.
7.5 ABBVIE INC.
7.6 BRISTOL MYERS SQUIBB COMPANY
7.7 DICERNA PHARMACEUTICALS
7.8 ROCHE
7.9 ARBUTUS PHARMA
7.10 NOVARTIS AG
7.11 ASTRAZENECA
7.12 BAYER AG
7.13 OTHERS
Chapter 8: Global Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Drug Class
8.2.1 Nucleotide Analog Reverse Transcriptase Inhibitors
8.2.2 Monoclonal Antibody
8.2.3 Interferon
8.2.4 Non-structural Protein 5A (NS5A) Inhibitors
8.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
8.2.6 Multi-Class Combination
8.2.7 Others
8.3 Historic and Forecasted Market Size By Type
8.3.1 Therapeutics
8.3.2 Vaccine
8.4 Historic and Forecasted Market Size By End Users
8.4.1 Men
8.4.2 Women
8.4.3 Children
Chapter 9: North America Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Drug Class
9.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
9.4.2 Monoclonal Antibody
9.4.3 Interferon
9.4.4 Non-structural Protein 5A (NS5A) Inhibitors
9.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
9.4.6 Multi-Class Combination
9.4.7 Others
9.5 Historic and Forecasted Market Size By Type
9.5.1 Therapeutics
9.5.2 Vaccine
9.6 Historic and Forecasted Market Size By End Users
9.6.1 Men
9.6.2 Women
9.6.3 Children
9.7 Historic and Forecast Market Size by Country
9.7.1 U.S.
9.7.2 Canada
9.7.3 Mexico
Chapter 10: Europe Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Drug Class
10.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
10.4.2 Monoclonal Antibody
10.4.3 Interferon
10.4.4 Non-structural Protein 5A (NS5A) Inhibitors
10.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
10.4.6 Multi-Class Combination
10.4.7 Others
10.5 Historic and Forecasted Market Size By Type
10.5.1 Therapeutics
10.5.2 Vaccine
10.6 Historic and Forecasted Market Size By End Users
10.6.1 Men
10.6.2 Women
10.6.3 Children
10.7 Historic and Forecast Market Size by Country
10.7.1 Germany
10.7.2 U.K.
10.7.3 France
10.7.4 Italy
10.7.5 Russia
10.7.6 Spain
Chapter 11: Asia-Pacific Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Drug Class
11.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
11.4.2 Monoclonal Antibody
11.4.3 Interferon
11.4.4 Non-structural Protein 5A (NS5A) Inhibitors
11.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
11.4.6 Multi-Class Combination
11.4.7 Others
11.5 Historic and Forecasted Market Size By Type
11.5.1 Therapeutics
11.5.2 Vaccine
11.6 Historic and Forecasted Market Size By End Users
11.6.1 Men
11.6.2 Women
11.6.3 Children
11.7 Historic and Forecast Market Size by Country
11.7.1 China
11.7.2 India
11.7.3 Japan
11.7.4 Southeast Asia
Chapter 12: South America Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Drug Class
12.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
12.4.2 Monoclonal Antibody
12.4.3 Interferon
12.4.4 Non-structural Protein 5A (NS5A) Inhibitors
12.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
12.4.6 Multi-Class Combination
12.4.7 Others
12.5 Historic and Forecasted Market Size By Type
12.5.1 Therapeutics
12.5.2 Vaccine
12.6 Historic and Forecasted Market Size By End Users
12.6.1 Men
12.6.2 Women
12.6.3 Children
12.7 Historic and Forecast Market Size by Country
12.7.1 Brazil
12.7.2 Argentina
Chapter 13: Middle East & Africa Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Drug Class
13.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
13.4.2 Monoclonal Antibody
13.4.3 Interferon
13.4.4 Non-structural Protein 5A (NS5A) Inhibitors
13.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
13.4.6 Multi-Class Combination
13.4.7 Others
13.5 Historic and Forecasted Market Size By Type
13.5.1 Therapeutics
13.5.2 Vaccine
13.6 Historic and Forecasted Market Size By End Users
13.6.1 Men
13.6.2 Women
13.6.3 Children
13.7 Historic and Forecast Market Size by Country
13.7.1 Saudi Arabia
13.7.2 South Africa
Chapter 14 Investment Analysis
Chapter 15 Analyst Viewpoint and Conclusion
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Drug Class
3.2 By Type
3.3 By End Users
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
3.5.1 Drivers
3.5.2 Restraints
3.5.3 Opportunities
3.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 4: Hepatitis B Virus [HBV] Market by Drug Class
4.1 Hepatitis B Virus [HBV] Market Overview Snapshot and Growth Engine
4.2 Hepatitis B Virus [HBV] Market Overview
4.3 Nucleotide Analog Reverse Transcriptase Inhibitors
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size (2016-2028F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Nucleotide Analog Reverse Transcriptase Inhibitors: Grographic Segmentation
4.4 Monoclonal Antibody
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size (2016-2028F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Monoclonal Antibody: Grographic Segmentation
4.5 Interferon
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size (2016-2028F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Interferon: Grographic Segmentation
4.6 Non-structural Protein 5A (NS5A) Inhibitors
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size (2016-2028F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Non-structural Protein 5A (NS5A) Inhibitors: Grographic Segmentation
4.7 Nucleotide Analog NS5B Polymerase Inhibitors
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size (2016-2028F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Nucleotide Analog NS5B Polymerase Inhibitors: Grographic Segmentation
4.8 Multi-Class Combination
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size (2016-2028F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Multi-Class Combination: Grographic Segmentation
4.9 Others
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size (2016-2028F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Others: Grographic Segmentation
Chapter 5: Hepatitis B Virus [HBV] Market by Type
5.1 Hepatitis B Virus [HBV] Market Overview Snapshot and Growth Engine
5.2 Hepatitis B Virus [HBV] Market Overview
5.3 Therapeutics
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Therapeutics: Grographic Segmentation
5.4 Vaccine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Vaccine: Grographic Segmentation
Chapter 6: Hepatitis B Virus [HBV] Market by End Users
6.1 Hepatitis B Virus [HBV] Market Overview Snapshot and Growth Engine
6.2 Hepatitis B Virus [HBV] Market Overview
6.3 Men
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Men: Grographic Segmentation
6.4 Women
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Women: Grographic Segmentation
6.5 Children
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Children: Grographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Hepatitis B Virus [HBV] Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Ansoff Matrix
7.1.5 Hepatitis B Virus [HBV] Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Hepatitis B Virus [HBV] Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 F HOFFMANN-LA ROCHE LTD
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 MERCK & CO. INC.
7.4 GILEAD SCIENCES INC.
7.5 ABBVIE INC.
7.6 BRISTOL MYERS SQUIBB COMPANY
7.7 DICERNA PHARMACEUTICALS
7.8 ROCHE
7.9 ARBUTUS PHARMA
7.10 NOVARTIS AG
7.11 ASTRAZENECA
7.12 BAYER AG
7.13 OTHERS
Chapter 8: Global Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Drug Class
8.2.1 Nucleotide Analog Reverse Transcriptase Inhibitors
8.2.2 Monoclonal Antibody
8.2.3 Interferon
8.2.4 Non-structural Protein 5A (NS5A) Inhibitors
8.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
8.2.6 Multi-Class Combination
8.2.7 Others
8.3 Historic and Forecasted Market Size By Type
8.3.1 Therapeutics
8.3.2 Vaccine
8.4 Historic and Forecasted Market Size By End Users
8.4.1 Men
8.4.2 Women
8.4.3 Children
Chapter 9: North America Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Drug Class
9.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
9.4.2 Monoclonal Antibody
9.4.3 Interferon
9.4.4 Non-structural Protein 5A (NS5A) Inhibitors
9.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
9.4.6 Multi-Class Combination
9.4.7 Others
9.5 Historic and Forecasted Market Size By Type
9.5.1 Therapeutics
9.5.2 Vaccine
9.6 Historic and Forecasted Market Size By End Users
9.6.1 Men
9.6.2 Women
9.6.3 Children
9.7 Historic and Forecast Market Size by Country
9.7.1 U.S.
9.7.2 Canada
9.7.3 Mexico
Chapter 10: Europe Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Drug Class
10.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
10.4.2 Monoclonal Antibody
10.4.3 Interferon
10.4.4 Non-structural Protein 5A (NS5A) Inhibitors
10.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
10.4.6 Multi-Class Combination
10.4.7 Others
10.5 Historic and Forecasted Market Size By Type
10.5.1 Therapeutics
10.5.2 Vaccine
10.6 Historic and Forecasted Market Size By End Users
10.6.1 Men
10.6.2 Women
10.6.3 Children
10.7 Historic and Forecast Market Size by Country
10.7.1 Germany
10.7.2 U.K.
10.7.3 France
10.7.4 Italy
10.7.5 Russia
10.7.6 Spain
Chapter 11: Asia-Pacific Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Drug Class
11.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
11.4.2 Monoclonal Antibody
11.4.3 Interferon
11.4.4 Non-structural Protein 5A (NS5A) Inhibitors
11.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
11.4.6 Multi-Class Combination
11.4.7 Others
11.5 Historic and Forecasted Market Size By Type
11.5.1 Therapeutics
11.5.2 Vaccine
11.6 Historic and Forecasted Market Size By End Users
11.6.1 Men
11.6.2 Women
11.6.3 Children
11.7 Historic and Forecast Market Size by Country
11.7.1 China
11.7.2 India
11.7.3 Japan
11.7.4 Southeast Asia
Chapter 12: South America Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Drug Class
12.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
12.4.2 Monoclonal Antibody
12.4.3 Interferon
12.4.4 Non-structural Protein 5A (NS5A) Inhibitors
12.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
12.4.6 Multi-Class Combination
12.4.7 Others
12.5 Historic and Forecasted Market Size By Type
12.5.1 Therapeutics
12.5.2 Vaccine
12.6 Historic and Forecasted Market Size By End Users
12.6.1 Men
12.6.2 Women
12.6.3 Children
12.7 Historic and Forecast Market Size by Country
12.7.1 Brazil
12.7.2 Argentina
Chapter 13: Middle East & Africa Hepatitis B Virus [HBV] Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Drug Class
13.4.1 Nucleotide Analog Reverse Transcriptase Inhibitors
13.4.2 Monoclonal Antibody
13.4.3 Interferon
13.4.4 Non-structural Protein 5A (NS5A) Inhibitors
13.4.5 Nucleotide Analog NS5B Polymerase Inhibitors
13.4.6 Multi-Class Combination
13.4.7 Others
13.5 Historic and Forecasted Market Size By Type
13.5.1 Therapeutics
13.5.2 Vaccine
13.6 Historic and Forecasted Market Size By End Users
13.6.1 Men
13.6.2 Women
13.6.3 Children
13.7 Historic and Forecast Market Size by Country
13.7.1 Saudi Arabia
13.7.2 South Africa
Chapter 14 Investment Analysis
Chapter 15 Analyst Viewpoint and Conclusion
| Hepatitis B Virus [HBV] Market - In-Depth Insights & Analysis | |||
|---|---|---|---|
| Segmentations | by Type |
| |
| by Type |
| ||
| by End Users |
| ||
| by Region |
| ||
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. HEPATITIS B VIRUS [HBV] MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. HEPATITIS B VIRUS [HBV] MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. HEPATITIS B VIRUS [HBV] MARKET COMPETITIVE RIVALRY
TABLE 005. HEPATITIS B VIRUS [HBV] MARKET THREAT OF NEW ENTRANTS
TABLE 006. HEPATITIS B VIRUS [HBV] MARKET THREAT OF SUBSTITUTES
TABLE 007. HEPATITIS B VIRUS [HBV] MARKET BY DRUG CLASS
TABLE 008. NUCLEOTIDE ANALOG REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 009. MONOCLONAL ANTIBODY MARKET OVERVIEW (2016-2028)
TABLE 010. INTERFERON MARKET OVERVIEW (2016-2028)
TABLE 011. NON-STRUCTURAL PROTEIN 5A (NS5A) INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 012. NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 013. MULTI-CLASS COMBINATION MARKET OVERVIEW (2016-2028)
TABLE 014. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 015. HEPATITIS B VIRUS [HBV] MARKET BY TYPE
TABLE 016. THERAPEUTICS MARKET OVERVIEW (2016-2028)
TABLE 017. VACCINE MARKET OVERVIEW (2016-2028)
TABLE 018. HEPATITIS B VIRUS [HBV] MARKET BY END USERS
TABLE 019. MEN MARKET OVERVIEW (2016-2028)
TABLE 020. WOMEN MARKET OVERVIEW (2016-2028)
TABLE 021. CHILDREN MARKET OVERVIEW (2016-2028)
TABLE 022. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 023. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 024. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 025. N HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 026. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 027. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 028. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 029. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 030. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 031. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 032. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 033. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 037. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 038. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 039. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 040. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 041. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 042. F HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 043. F HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 044. F HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 045. F HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. MERCK & CO. INC.: SNAPSHOT
TABLE 046. MERCK & CO. INC.: BUSINESS PERFORMANCE
TABLE 047. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 048. MERCK & CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. GILEAD SCIENCES INC.: SNAPSHOT
TABLE 049. GILEAD SCIENCES INC.: BUSINESS PERFORMANCE
TABLE 050. GILEAD SCIENCES INC.: PRODUCT PORTFOLIO
TABLE 051. GILEAD SCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. ABBVIE INC.: SNAPSHOT
TABLE 052. ABBVIE INC.: BUSINESS PERFORMANCE
TABLE 053. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 054. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. BRISTOL MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 055. BRISTOL MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 056. BRISTOL MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 057. BRISTOL MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. DICERNA PHARMACEUTICALS: SNAPSHOT
TABLE 058. DICERNA PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 059. DICERNA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 060. DICERNA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. ROCHE: SNAPSHOT
TABLE 061. ROCHE: BUSINESS PERFORMANCE
TABLE 062. ROCHE: PRODUCT PORTFOLIO
TABLE 063. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. ARBUTUS PHARMA: SNAPSHOT
TABLE 064. ARBUTUS PHARMA: BUSINESS PERFORMANCE
TABLE 065. ARBUTUS PHARMA: PRODUCT PORTFOLIO
TABLE 066. ARBUTUS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. NOVARTIS AG: SNAPSHOT
TABLE 067. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 068. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 069. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. ASTRAZENECA: SNAPSHOT
TABLE 070. ASTRAZENECA: BUSINESS PERFORMANCE
TABLE 071. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 072. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. BAYER AG: SNAPSHOT
TABLE 073. BAYER AG: BUSINESS PERFORMANCE
TABLE 074. BAYER AG: PRODUCT PORTFOLIO
TABLE 075. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. OTHERS: SNAPSHOT
TABLE 076. OTHERS: BUSINESS PERFORMANCE
TABLE 077. OTHERS: PRODUCT PORTFOLIO
TABLE 078. OTHERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. NUCLEOTIDE ANALOG REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 013. MONOCLONAL ANTIBODY MARKET OVERVIEW (2016-2028)
FIGURE 014. INTERFERON MARKET OVERVIEW (2016-2028)
FIGURE 015. NON-STRUCTURAL PROTEIN 5A (NS5A) INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 016. NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 017. MULTI-CLASS COMBINATION MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 019. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY TYPE
FIGURE 020. THERAPEUTICS MARKET OVERVIEW (2016-2028)
FIGURE 021. VACCINE MARKET OVERVIEW (2016-2028)
FIGURE 022. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY END USERS
FIGURE 023. MEN MARKET OVERVIEW (2016-2028)
FIGURE 024. WOMEN MARKET OVERVIEW (2016-2028)
FIGURE 025. CHILDREN MARKET OVERVIEW (2016-2028)
FIGURE 026. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. EUROPE HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. HEPATITIS B VIRUS [HBV] MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. HEPATITIS B VIRUS [HBV] MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. HEPATITIS B VIRUS [HBV] MARKET COMPETITIVE RIVALRY
TABLE 005. HEPATITIS B VIRUS [HBV] MARKET THREAT OF NEW ENTRANTS
TABLE 006. HEPATITIS B VIRUS [HBV] MARKET THREAT OF SUBSTITUTES
TABLE 007. HEPATITIS B VIRUS [HBV] MARKET BY DRUG CLASS
TABLE 008. NUCLEOTIDE ANALOG REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 009. MONOCLONAL ANTIBODY MARKET OVERVIEW (2016-2028)
TABLE 010. INTERFERON MARKET OVERVIEW (2016-2028)
TABLE 011. NON-STRUCTURAL PROTEIN 5A (NS5A) INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 012. NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
TABLE 013. MULTI-CLASS COMBINATION MARKET OVERVIEW (2016-2028)
TABLE 014. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 015. HEPATITIS B VIRUS [HBV] MARKET BY TYPE
TABLE 016. THERAPEUTICS MARKET OVERVIEW (2016-2028)
TABLE 017. VACCINE MARKET OVERVIEW (2016-2028)
TABLE 018. HEPATITIS B VIRUS [HBV] MARKET BY END USERS
TABLE 019. MEN MARKET OVERVIEW (2016-2028)
TABLE 020. WOMEN MARKET OVERVIEW (2016-2028)
TABLE 021. CHILDREN MARKET OVERVIEW (2016-2028)
TABLE 022. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 023. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 024. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 025. N HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 026. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 027. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 028. EUROPE HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 029. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 030. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 031. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 032. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 033. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 034. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 035. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 036. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 037. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 038. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY DRUG CLASS (2016-2028)
TABLE 039. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY TYPE (2016-2028)
TABLE 040. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET, BY END USERS (2016-2028)
TABLE 041. HEPATITIS B VIRUS [HBV] MARKET, BY COUNTRY (2016-2028)
TABLE 042. F HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 043. F HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 044. F HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 045. F HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. MERCK & CO. INC.: SNAPSHOT
TABLE 046. MERCK & CO. INC.: BUSINESS PERFORMANCE
TABLE 047. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 048. MERCK & CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. GILEAD SCIENCES INC.: SNAPSHOT
TABLE 049. GILEAD SCIENCES INC.: BUSINESS PERFORMANCE
TABLE 050. GILEAD SCIENCES INC.: PRODUCT PORTFOLIO
TABLE 051. GILEAD SCIENCES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. ABBVIE INC.: SNAPSHOT
TABLE 052. ABBVIE INC.: BUSINESS PERFORMANCE
TABLE 053. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 054. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. BRISTOL MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 055. BRISTOL MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 056. BRISTOL MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 057. BRISTOL MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. DICERNA PHARMACEUTICALS: SNAPSHOT
TABLE 058. DICERNA PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 059. DICERNA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 060. DICERNA PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. ROCHE: SNAPSHOT
TABLE 061. ROCHE: BUSINESS PERFORMANCE
TABLE 062. ROCHE: PRODUCT PORTFOLIO
TABLE 063. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. ARBUTUS PHARMA: SNAPSHOT
TABLE 064. ARBUTUS PHARMA: BUSINESS PERFORMANCE
TABLE 065. ARBUTUS PHARMA: PRODUCT PORTFOLIO
TABLE 066. ARBUTUS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. NOVARTIS AG: SNAPSHOT
TABLE 067. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 068. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 069. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. ASTRAZENECA: SNAPSHOT
TABLE 070. ASTRAZENECA: BUSINESS PERFORMANCE
TABLE 071. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 072. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. BAYER AG: SNAPSHOT
TABLE 073. BAYER AG: BUSINESS PERFORMANCE
TABLE 074. BAYER AG: PRODUCT PORTFOLIO
TABLE 075. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. OTHERS: SNAPSHOT
TABLE 076. OTHERS: BUSINESS PERFORMANCE
TABLE 077. OTHERS: PRODUCT PORTFOLIO
TABLE 078. OTHERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. NUCLEOTIDE ANALOG REVERSE TRANSCRIPTASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 013. MONOCLONAL ANTIBODY MARKET OVERVIEW (2016-2028)
FIGURE 014. INTERFERON MARKET OVERVIEW (2016-2028)
FIGURE 015. NON-STRUCTURAL PROTEIN 5A (NS5A) INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 016. NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITORS MARKET OVERVIEW (2016-2028)
FIGURE 017. MULTI-CLASS COMBINATION MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 019. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY TYPE
FIGURE 020. THERAPEUTICS MARKET OVERVIEW (2016-2028)
FIGURE 021. VACCINE MARKET OVERVIEW (2016-2028)
FIGURE 022. HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY END USERS
FIGURE 023. MEN MARKET OVERVIEW (2016-2028)
FIGURE 024. WOMEN MARKET OVERVIEW (2016-2028)
FIGURE 025. CHILDREN MARKET OVERVIEW (2016-2028)
FIGURE 026. NORTH AMERICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. EUROPE HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. ASIA PACIFIC HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. MIDDLE EAST & AFRICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. SOUTH AMERICA HEPATITIS B VIRUS [HBV] MARKET OVERVIEW BY COUNTRY (2016-2028)
Frequently Asked Questions :
What would be forecast period in the market research report?
The forecast period in the market research report is 2022-2028.
Who are the key players in Hepatitis B Virus [HBV] market?
The key players mentioned are F Hoffmann-La Roche Ltd, Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, Dicerna Pharmaceuticals, Roche, Arbutus Pharma, Novartis AG, AstraZeneca, Bayer AG, Others.
What are the segments of Hepatitis B Virus [HBV] market?
The Hepatitis B Virus [HBV] market is segmented into Drug Class, Type, End Users and region. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain; Rest of Europe), Asia-Pacific (China; India; Japan; Southeast Asia; Rest of APAC), Middle East & Africa (GCC Countries; South Africa; Rest of MEA), South America (Brazil; Argentina; Rest of South America).
What is the Hepatitis B Virus [HBV] market?
Hepatitis B Virus [HBV] Market size is projected to reach xxxx units by 2028 from an estimated xxxx unit in 2021, growing at a CAGR of xx% globally.
How big is the Hepatitis B Virus [HBV] market?
The global Hepatitis B Virus [HBV] market size was estimated at USD XX billion in 2021 and is expected to reach USD XX billion in 2028.
